文献速递妇科肿瘤

延长无铂间期策略在晚期卵巢癌中的随机对照试验:MITO-8、MaNGO、BGOG-Ov1、AGO-Ovar2.16、ENGOT-Ov1、GCIG研究

Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
PubMed 文献 · J Clin Oncol · 2017-08-21

MITO-8是一项开放标签、前瞻性、随机、优效性试验,纳入末次铂类治疗后6至12个月进展的卵巢癌患者215例,随机1:1分配至非铂类化疗后铂类化疗的实验序列或标准反向序列。实验组无总生存获益(中位21.8 vs 24.5个月;HR 1.38;95%CI 0.99-1.94;P=.06),且序列后无进展生存显著缩短(中位12.8 vs 16.4个月;HR 1.41;95%CI 1.04-1.92;P=.025)。结论支持部分铂敏感卵巢癌患者不应延迟铂类化疗而优先使用非铂类药物。

要点

  • 部分铂敏感卵巢癌患者延长无铂间期未改善总生存(HR 1.38;95%CI 0.99-1.94;P=.06)。
  • 实验组序列后无进展生存显著缩短(中位12.8 vs 16.4个月;HR 1.41;P=.025)。
  • 实验组三周期后整体生活质量变化更差。

核心结论

  • MITO-8支持以下推荐:部分铂敏感卵巢癌患者不应延迟铂类化疗而优先使用非铂类药物。
  • 在此类患者未来新药试验中,应以铂类化疗作为对照臂。

研究设计与样本

  • 开放标签、前瞻性、随机、优效性试验,纳入末次铂类治疗后6至12个月进展的卵巢癌患者。
  • 患者随机1:1分配至非铂类化疗后铂类化疗的实验序列或标准反向序列。
  • 共入组215例患者(标准组108例,实验组107例),因入组缓慢提前终止。

主要发现

  • 实验组无铂间期延长(中位7.8 vs 0.01个月)。
  • 实验组无总生存获益(中位21.8 vs 24.5个月;HR 1.38;95%CI 0.99-1.94;P=.06)。
  • 实验组序列后无进展生存显著缩短(中位12.8 vs 16.4个月;HR 1.41;95%CI 1.04-1.92;P=.025)。
  • 实验组三周期后整体生活质量变化更差。
  • 不良事件发生率两组间仅见轻微差异。

关键数值与推荐

  • 无进展生存:实验组中位12.8个月 vs 标准组中位16.4个月(HR 1.41;95%CI 1.04-1.92;P=.025)。
  • 总生存:实验组中位21.8个月 vs 标准组中位24.5个月(HR 1.38;95%CI 0.99-1.94;P=.06)。
  • 无铂间期:实验组中位7.8个月 vs 标准组中位0.01个月。

临床怎么用

  • 部分铂敏感卵巢癌患者不应延迟铂类化疗而优先使用非铂类药物(原文结论支持此推荐)。
  • 未来该人群新药试验应以铂类化疗作为对照臂(原文结论)。

局限性

  • 试验因入组缓慢提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Platinum-based chemotherapy (PBC) for patients with progressing ovarian cancer (OC) is more effective with a longer time interval from previous platinum treatment (platinum-free interval [PFI]). In 1999, it was hypothesized that prolonging PFI with single-agent non-PBC (NPBC) may offer a strategy to improve overall outcome. MITO-8 aimed to verify this hypothesis commonly used in clinical practice although it has not been prospectively tested. Methods MITO-8 is an open-label, prospective, randomized, superiority trial. Patients with OC who experienced disease progression 6 to 12 months after their last platinum treatment were randomly assigned 1:1 to the experimental sequence of NPBC followed by PBC at subsequent relapse or the standard reverse treatment sequence. Overall survival (OS) was the primary end point. Results Two hundred fifteen patients were enrolled (standard arm [n = 108]; experimental arm [n = 107]). The trial ended before planned because of slow enrollment. PFI was prolonged in the experimental arm (median, 7.8 v 0.01 months). There was no OS benefit in the experimental arm (median, 21.8 v 24.5 months; hazard ratio, 1.38; 95% CI, 0.99 to 1.94; P = .06). Progression-free survival after the sequence was significantly shorter in the experimental arm (median, 12.8 v 16.4 months; hazard ratio, 1.41; 95% CI, 1.04 to 1.92; P = .025). Global quality-of-life change after three cycles was worse in the experimental arm. Slight differences were observed in the incidence of adverse effects. Conclusion MITO-8 supports the recommendation that PBC not be delayed in favor of an NPBC in patients with partially platinum-sensitive OC. PBC should be used as a control arm in future trials of new drugs in this setting.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pignata S, Scambia G, Bologna A, et al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study. J Clin Oncol. 2017. PMID: 28825853. doi:10.1200/JCO.2017.73.4293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。